二磷酸腺苷受体拮抗剂类抗血小板药物研究进展  

Progression of ADP receptor inhibitors antiplatelet drugs

作　　者：吴雅凝[1] 赵娣[1] 李宁[1] 陈西敬[1] 

机构地区：[1]中国药科大学药代研究中心

出　　处：《中国临床药理学与治疗学》2010年第12期1434-1440,共7页Chinese Journal of Clinical Pharmacology and Therapeutics

摘　　要：抗血小板治疗对急性冠脉综合症和预防经皮冠脉介入手术患者形成血栓的效果很好,可以显著降低上述两种疾病的致死率和发病率。目前最常用的药物是阿司匹林与氯吡格雷,但是一些临床数据表明,这两种药物的合用并不是对所有的病人都有很好的疗效,这可能会造成一些心血管方面的不良反应。所以,对一些有前途的、新的抗血小板药物进行进一步的研究就显得十分有必要。本文对二磷酸腺苷受体拮抗剂类抗血小板药物(如氯吡格雷、普拉格雷、替卡格雷、坎格雷洛等)的代谢和作用特点进行综述,为临床用药提供参考。Antiplatelet therapy has a well established role as an antithrombotic agent in the settings of percutaneous coronary intervention and acute coronary sydromes,and it has been successful in reducing mortality and morbidity in the two diseases above-mentioned.Recently,the most commonly used drugs were aspirin and clopidogrel,but some clinical data indicate that the combination of these two drugs doesn＇t work well for all the patients,which may cause some cardiovascular adverse reactions.Therefore,it＇s extremely necessary to do some further research on a number of promising new anti-platelet drugs.This article reviews the metabolic and onset characteristic of ADP receptor inhibitors antiplatelet drugs（e.g.clopidogrel,prasugrel,ticagrelor,cangrelor） in the treatment of cardiovascular disease and provide a reference for clinical medicine.

关 键 词：抗血小板药物 P2Y12受体 普拉格雷 替卡格雷 坎格雷洛 

分 类 号：R972.7[医药卫生—药品]